Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 May;98(5):508-516.
doi: 10.1111/ejh.12864. Epub 2017 Mar 9.

The Myeloma Patient Outcome Scale is the first quality of life tool developed for clinical use and validated in patients with follicular lymphoma

Joanna M Davies  1 , Thomas R Osborne  2 , Polly M Edmonds  3 , Steve A Schey  4 , Steve Devereux  4 , Irene J Higginson  1 , Christina Ramsenthaler  1   5
Affiliations

The Myeloma Patient Outcome Scale is the first quality of life tool developed for clinical use and validated in patients with follicular lymphoma

Joanna M Davies et al. Eur J Haematol. 2017 May.

Abstract

Objectives: The development of novel agents and an ageing population has led to an increasing number of patients with follicular lymphoma (FL) living longer with their disease. Health-related quality of life (HRQOL) is a priority for patients and should guide clinical decisions. The Myeloma Patient Outcome Scale (MyPOS), originally developed for myeloma, was validated in a cross-sectional survey recruiting 124 FL patients.

Methods: Content and construct validity, structural validity using confirmatory factor analyses, reliability and acceptability were evaluated.

Results: Three subscales were indicated: symptoms and function, emotional response, and healthcare support. MyPOS symptom and function scores were higher (worse) in participants with poorer ECOG performance status (F=26.2, P<.000) and discriminated between patients on and off treatment. Good convergent and discriminant validity in comparison to the EORTC-QLQ-C30 and FACT-Lym were demonstrated. Internal consistency was good; α coefficient 0.70-0.95 for the total MyPOS score and subscales.

Conclusion: The MyPOS is valid, reliable and acceptable, and can be used to support clinical care of FL patients. This is the first measurement tool developed specially for use in clinical practice that has been validated for use in people with FL. Further longitudinal validation is now required to support its use in outcome measurement.

Keywords: Follicular lymphoma; factor analysis; non-Hodgkin lymphoma; psychometrics; quality of life; questionnaire validation.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Known group comparisons showing MyPOS symptoms and function subscale scores (mean and 95% CI) by treatment status and ECOG performance status (n=120)
See this image and copyright information in PMC

References

    1. Steliarova‐Foucher E, O'Callaghan M, Ferlay J, et al. European Cancer Observatory: Cancer Incidence, Mortality, Prevalence and Survival in Europe. Version 1.0 (September 2012) European Network of Cancer Registries, International Agency for Research on Cancer. Available from http://eco.iarc.fr. Accessed on November 30, 2016.
    1. Smith A, Crouch S, Lax S, et al. Lymphoma incidence, survival and prevalence 2004‐2014: sub‐type analyses from the UK's Haematological Malignancy Research Network. Br J Cancer. 2015;112:1575‐1584. - PMC - PubMed
    1. Shankland KR, Armitage JO, Hancock BW. Non‐Hodgkin lymphoma. Lancet. 2012;380:848‐857. - PubMed
    1. Link BK, Maurer MJ, Nowakowski GS, et al. Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource. J Clin Oncol. 2013;31:3272‐3278. - PMC - PubMed
    1. Ansell SM. Follicular lymphoma: watch and wait is watch and worry. Lancet Oncol. 2014;15:368‐369. - PubMed